Multifunctional, Nanoparticle-Based, Therapies for the Treatment of Periodontal D

描述（由申请人提供）：本阶段SBIR提案的目的是为牙周病的治疗提供改进的疗法。牙周病是一种慢性口腔传染病，影响美国约35%的成年人口，或略超过4000万人。1 -12在严重的情况下，牙周病可导致底层骨结构的失败，并需要手术拔牙和更换牙齿。仅在美国，19984年治疗牙周病的费用估计为每年190亿美元。 提出的创新是生产多功能的，表面改性的纳米颗粒载体，其被设计为与硬组织表面和细菌生物膜牢固结合，并可提供多种治疗有效载荷。因为纳米颗粒可以结合到组织表面和细菌生物膜，载体可以在牙周袋内具有实质性（持久的）治疗效果，这是当前疗法的主要缺点。将药物载体定位和化学附着在牙周组织内的能力是所提出的创新的主要优点，因为常规疗法都遭受药物通过龈沟液（唾液）的周转而快速清除的事实。7所提出的创新如果成功，将能够管理多种治疗化学物质并在延长的时间段内以有效水平将它们递送到牙周袋和牙龈组织，而无需临床医生的反复干预。 公共卫生相关性：牙周病是一种慢性口腔传染病，影响美国约35%的成年人口，或略多于4000万人。该SBIR旨在克服目前牙周病治疗的缺点，并提供一种能够管理多种治疗化学物质的治疗，在延长的时间段内将它们递送到疾病部位，而无需临床医生的重复干预。

DESCRIPTION (provided by applicant): The objective of this Phase I SBIR proposal is to provide improved therapies for the treatment of periodontal disease. Periodontal Disease is a chronic infectious disease of the oral cavity that effects about 35 % of the adult population in the United States, or slightly more than 40 million people.1-12 In severe cases, periodontal disease can lead to a failure of the underlying bone structure and necessitate surgical extraction and replacement of the teeth. In the U.S alone, the cost of treating periodontal disease was estimated at $19 billion dollars annually in 19984. The innovation proposed is to produce multifunctional, surface-modified nanoparticle carriers that are designed to bind robustly to hard tissue surfaces and bacterial biofilms, and may deliver multiple therapeutic payloads. Because the nanoparticles may bind to tissue surfaces and to bacterial biofilms, the carriers may have substantive (long lasting) therapeutic effects within the periodontal pocket, a major shortcoming of current therapies. The ability to localize and chemically attach the drug-carrier within the periodontium is a major advantage of the proposed innovation, since conventional therapies all suffer from the fact that the drugs are rapidly cleared by the turnover of gingival crevicular fluid (saliva).7 The proposed innovation, if successful, will be capable of managing multiple therapeutic chemistries and deliver them to the periodontal pocket and gingival tissues at efficacious levels over an extended period of time, without repeated intervention from a clinician. PUBLIC HEALTH RELEVANCE: Periodontal Disease is a chronic infectious disease of the oral cavity that effects about 35 % of the adult population in the United States, or slightly more than 40 million people. This SBIR seeks to overcome the shortcomings of current therapies for periodontal disease, and to provide a therapy that is capable of managing multiple therapeutic chemistries, delivering them to disease sites over an extended period of time, without the repeated intervention from a clinician.